Figure 2.
Potent mAbs target Pfs48/45 D1 and D3
(A) mAbs were tested at 100 μg/mL in a barcoded membrane-feeding assay using Anopheles stephensi mosquitoes and transgenic Plasmodium falciparum NF54 parasites that express a luciferase reporter.27 The figure shows the proportion of mosquitoes with low infection (>90% reduction in oocyst intensity relative to the vehicle controls) 8 days after feeding. Note that five mAbs, including RUPA-160, were not available at the time the barcoded membrane-feeding assay was performed and were only tested in a standard membrane-feeding assay (Figure S3D).
(B–D) D1-specific (B), D2-specific (C), and D3-specific (D) mAbs that showed >95% TRA in standard membrane-feeding assay (SMFA) at 100 μg/mL (Figure S3D) were titrated to determine their potency.
(E) The most potent D3-specific mAbs were further titrated and tested head-to-head with TB31F in the single SMFA experiment.
mAbs are colored according to domain specificity and TRA values (B–E) were based on single SMFA experiments with 20 mosquitoes per condition and calculated as the percentage reduction in oocyst intensity compared with a negative control. Raw SMFA data and 95% confidence intervals are presented in Table S7.
See also Figure S3.